Natera, Inc. NTRA

Natera Positioned To Capture Growing $20 Billion MRD Opportunity-Analyst

Benzinga · 99d ago

Natera's Signatera Data Suggests Select Breast Cancer Patients Could Skip Surgery

Benzinga · 113d ago

3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade

The Motley Fool · 144d ago

Billionaire Stanley Druckenmiller Is Betting Big on These 2 Stocks

The Motley Fool · 150d ago

Esoteric Testing Research Report 2026 - Global $41.5+ Bn Market Trends, Opportunities, and Forecasts to 2031

GlobeNewswire Inc. · 173d ago

Non-Invasive Prenatal Testing Market is expected to generate a revenue of USD 9.83 Billion by 2031, Globally, at 17.01% CAGR: Verified Market Research®

GlobeNewswire Inc. · 194d ago

Reproductive Genetics Market Size to Reach USD 16.67 Billion in 2032 Amid Increasing Demand for Genetic Testing

GlobeNewswire Inc. · 204d ago

Natera New Test Data Could Change How Doctors Manage Breast Cancer

Benzinga · 223d ago

Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal?

Benzinga · 229d ago

Natera Buys Foresight To Boost Super-Early Cancer Detection Tech

Benzinga · 229d ago

30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks

The Motley Fool · 234d ago

Global Liquid Biopsy Market Set to Reach USD 7.05 Billion by 2030 | MarketsandMarkets™

GlobeNewswire Inc. · 334d ago

Personalis (PSNL) Q2 Revenue Falls 24%

The Motley Fool · 350d ago

U.S. Minimal Residual Disease Testing Market Trends Analysis Report 2025-2033 | Integration with Personalized Medicines, & Rising Incidence and Prevalence of Hematological Malignancies Fueling Growth

GlobeNewswire Inc. · 362d ago

Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape

GlobeNewswire Inc. · 405d ago

Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - Precision Medicine and Early Relapse Detection Drive MRD Testing Demand Worldwide

GlobeNewswire Inc. · 470d ago

Liquid Biopsy Market Worth US$11.3 billion at a robust CAGR of 11.9% | MarketsandMarkets™.

GlobeNewswire Inc. · 511d ago

Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings

The Motley Fool · 559d ago

Liquid Biopsy Market to Reach $ 32.54 Billion, Globally, by 2033 at 11.61% CAGR: The Brainy Insights

GlobeNewswire Inc. · 677d ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

The Motley Fool · 701d ago

Laboratory-Developed Tests (LDTs) World Market Forecast Report to 2028, with Coverage of the Effects of the FDA's New "Medical Devices: Laboratory Developed Tests" Rule, Passed in April 2024

GlobeNewswire Inc. · 706d ago

Natera executive sells shares worth over $57k - Investing.com

Investing.com · 728d ago

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Zacks Investment Research · 771d ago

Breaking Down Natera: 10 Analysts Share Their Views

Benzinga · 779d ago

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Zacks Investment Research · 782d ago